160 related articles for article (PubMed ID: 15622005)
1. Treatment of lung cancer using clinically relevant oral doses of the cyclooxygenase-2 inhibitor rofecoxib: potential value as adjuvant therapy after surgery.
Tanaka T; Delong PA; Amin K; Henry A; Kruklitis R; Kapoor V; Kaiser LR; Albelda SM
Ann Surg; 2005 Jan; 241(1):168-78. PubMed ID: 15622005
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.
Yao M; Kargman S; Lam EC; Kelly CR; Zheng Y; Luk P; Kwong E; Evans JF; Wolfe MM
Cancer Res; 2003 Feb; 63(3):586-92. PubMed ID: 12566300
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer.
O'Byrne KJ; Danson S; Dunlop D; Botwood N; Taguchi F; Carbone D; Ranson M
J Clin Oncol; 2007 Aug; 25(22):3266-73. PubMed ID: 17664473
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the effects of cyclooxygenase-2 inhibition in the regulation of apoptosis in human small and non-small cell lung cancer cell lines.
Alam M; Wang JH; Coffey JC; Qadri SS; O'Donnell A; Aherne T; Redmond HP
Ann Surg Oncol; 2007 Sep; 14(9):2678-84. PubMed ID: 17602268
[TBL] [Abstract][Full Text] [Related]
5. Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy.
DeLong P; Tanaka T; Kruklitis R; Henry AC; Kapoor V; Kaiser LR; Sterman DH; Albelda SM
Cancer Res; 2003 Nov; 63(22):7845-52. PubMed ID: 14633712
[TBL] [Abstract][Full Text] [Related]
6. Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer.
Yao M; Zhou W; Sangha S; Albert A; Chang AJ; Liu TC; Wolfe MM
Clin Cancer Res; 2005 Feb; 11(4):1618-28. PubMed ID: 15746067
[TBL] [Abstract][Full Text] [Related]
7. Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine.
Haas AR; Sun J; Vachani A; Wallace AF; Silverberg M; Kapoor V; Albelda SM
Clin Cancer Res; 2006 Jan; 12(1):214-22. PubMed ID: 16397045
[TBL] [Abstract][Full Text] [Related]
8. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
Chan CC; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY; Gordon R; Gresser M; Guay J; Kargman S; Kennedy B; Leblanc Y; Leger S; Mancini J; O'Neill GP; Ouellet M; Patrick D; Percival MD; Perrier H; Prasit P; Rodger I
J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562
[TBL] [Abstract][Full Text] [Related]
9. Surgically induced accelerated local and distant tumor growth is significantly attenuated by selective COX-2 inhibition.
Qadri SS; Wang JH; Coffey JC; Alam M; O'Donnell A; Aherne T; Redmond HP
Ann Thorac Surg; 2005 Mar; 79(3):990-5; discussion 990-5. PubMed ID: 15734421
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans.
Schwartz JI; Chan CC; Mukhopadhyay S; McBride KJ; Jones TM; Adcock S; Moritz C; Hedges J; Grasing K; Dobratz D; Cohen RA; Davidson MH; Bachmann KA; Gertz BJ
Clin Pharmacol Ther; 1999 Jun; 65(6):653-60. PubMed ID: 10391671
[TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase-2 inhibitor, nimesulide, improves radiation treatment against non-small cell lung cancer both in vitro and in vivo.
Grimes KR; Warren GW; Fang F; Xu Y; St Clair WH
Oncol Rep; 2006 Oct; 16(4):771-6. PubMed ID: 16969492
[TBL] [Abstract][Full Text] [Related]
12. [Effects of rofecoxib on angiogenesis of pancreatic cancer xenograft in nude mice].
Zhou XC; Tang CW; Liu CL; Wang CH
Ai Zheng; 2004 Apr; 23(4):376-80. PubMed ID: 15087022
[TBL] [Abstract][Full Text] [Related]
13. Combined therapy with COX-2 inhibitor and 20-HETE inhibitor reduces colon tumor growth and the adverse effects of ischemic stroke associated with COX-2 inhibition.
Zhang Y; Hoda MN; Zheng X; Li W; Luo P; Maddipati KR; Seki T; Ergul A; Wang MH
Am J Physiol Regul Integr Comp Physiol; 2014 Sep; 307(6):R693-703. PubMed ID: 24990856
[TBL] [Abstract][Full Text] [Related]
14. A rationale for surgical debulking to improve anti-PD1 therapy outcome in non small cell lung cancer.
Guisier F; Cousse S; Jeanvoine M; Thiberville L; Salaun M
Sci Rep; 2019 Nov; 9(1):16902. PubMed ID: 31729430
[TBL] [Abstract][Full Text] [Related]
15. [Cyclooxygenase 2 inhibitors and lung carcinoma].
Spano JP; Chouahnia K; Morère JF
Bull Cancer; 2004 May; 91 Suppl 2():S109-12. PubMed ID: 15899634
[TBL] [Abstract][Full Text] [Related]
16. Effect of rofecoxib on colon chemical carcinogenesis at colonic anastomotic area in the rat.
Noguera Aguilar JF; Amengual Antich I; Morón Canis JM; Plaza Martínez A; Martínez Córcoles JA; Tortajada Collado C; Pujol Tugores JJ
Rev Esp Enferm Dig; 2005 Jun; 97(6):405-15. PubMed ID: 16011415
[TBL] [Abstract][Full Text] [Related]
17. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model.
Ehrich EW; Dallob A; De Lepeleire I; Van Hecken A; Riendeau D; Yuan W; Porras A; Wittreich J; Seibold JR; De Schepper P; Mehlisch DR; Gertz BJ
Clin Pharmacol Ther; 1999 Mar; 65(3):336-47. PubMed ID: 10096266
[TBL] [Abstract][Full Text] [Related]
18. Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial.
Midgley RS; McConkey CC; Johnstone EC; Dunn JA; Smith JL; Grumett SA; Julier P; Iveson C; Yanagisawa Y; Warren B; Langman MJ; Kerr DJ
J Clin Oncol; 2010 Oct; 28(30):4575-80. PubMed ID: 20837956
[TBL] [Abstract][Full Text] [Related]
19. Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study.
Becerra CR; Frenkel EP; Ashfaq R; Gaynor RB
Int J Cancer; 2003 Jul; 105(6):868-72. PubMed ID: 12767075
[TBL] [Abstract][Full Text] [Related]
20. COX-2 inhibition demonstrates potent anti-proliferative effects on bladder cancer in vitro.
Mohseni H; Zaslau S; McFadden D; Riggs DR; Jackson BJ; Kandzari S
J Surg Res; 2004 Jun; 119(2):138-42. PubMed ID: 15145695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
